Novo Nordisk To End Sales Of New Insulin Drug In Germany
Reuters report Novo Nordisk will end sales of its new insulin drug Tresiba in Germany due to a dispute over pricing. The company announced it could not reach an agreement on price with the GKV-Spitzenverband, the German national association of statutory health insurance funds. להמשך קריאה
Animal Studies Examine How Metformin Works.
Animal studies into the mechanism behind vascular protective effects of metformin suggest its efficacy stems from blunting thioredoxin-interacting protein promoter (TXNIP) overexpression,. Such overexpression can result in poor glycemic control and endothelial dysfunction.
FDA Approves Non-Surgical Weight-Loss Device For Severely Obese Patients.
FDA approved “ReShape Dual Balloon Device” from ReShape Medical to treat severe obese patients with related conditions such as diabetes, high blood pressure and high cholesterol. The balloon is a temporary introduced in the body through the mouth and then inflated. It will be available to obese people who often don’t qualify for surgical weight-loss procedures.
Sanofi Announces Experimental Diabetes Drug Meets Goal In Late Stage-Trial.
Sanofi’s experimental diabetes treatment LixiLan [lixisenatide/insulin glargine] met its main goal in a late-stage trial, giving the drugmaker a potential competitor to Novo Nordisk Xultophy [insuline déglude/liraglutide]. The drug is a combination of the company’s top-selling insulin Lantus and Lyxumia.
Alefacept May Help People With Newly Diagnosed T1D Preserve Beta Cells Function.
Research suggests that taking two 12-week courses of alefacept – a drug already approved to treat psoriasis – may help people with newly diagnosed type 1 diabetes preserve some function in their beta cells. Individuals taking the medication required approximately 25 percent less insulin, and they had about half the rate of major hypoglycemia compared to those who took a placebo. The findings were published in the Journal of Clinical Investigation.
Researchers Identify Gene Mutation That Causes Severe Obesity And Type 2 Diabetes.
Researchers have identified a single-gene mutation that shuts down production of the carboxypeptidase-E (CPE) enzyme, and causes severe obesity and type 2 diabetes. This mutation affects insulin processing and appetite suppression and leads to intellectual disability and reproductive problems. The findings were published in PLoS One.
Researchers Design Fully Implantable Artificial Pancreas With Novel Algorithm.
Researchers developed a fully implantable insulin delivery and glucose sensing system guided by a novel algorithm. In computer testing, the device was able to maintain a tight glycemic range of 80-140 mg/dL, with no hypoglycemia 78 percent of the time. The researchers are expected to do follow-up testing of the device in animals. The research was partially funded by the NIH.
Mouse Study Provides Insight Into SCD1 Enzyme’s Role In Lipid Metabolism.
New insight into the structure and function of stearoyl-CoA desaturase-1 (SCD1), an enzyme homologue known to play a significant role in lipid metabolism, may provide the key to understanding how pharmacologic inhibition of SCD1 could be used to treat obesity, diabetes, and other metabolic diseases, according to a mouse study published online in the journal Nature. The NIH was one of the organizations funding the study.
Novo Nordisk’s Experimental Diabetes Drug Has Promising Late-Stage Clinical Trial.
Novo Nordisk announced its experimental once-weekly diabetes drug semaglutide showed successful results in clinical trial. Patients who had a 8.1% baseline HbA1c reading who were given 0.5 mg and 1.0 mg of the drug had improvements of 1.5% to 1.6%, respectively.